Effect of Low-dose Versus Standard-dose Iron Supplementation on the Gut Microbiome

Sponsor
University of Zurich (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05467423
Collaborator
(none)
30
2
3

Study Details

Study Description

Brief Summary

Iron deficiency is a common problem that is often treated with the administration of oral iron.

Most of the iron is not absorbed and remains in the intestine, where it influences the balance of gut bacteria.

This influence is usually undesirable and should be kept as small as possible. With lower iron doses, the amount of unabsorbed iron is smaller and therefore a smaller change in the intestinal bacteria composition is to be expected.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Iron
N/A

Detailed Description

Iron deficiency affects about one in five premenopausal women. The first line treatment for patients with iron deficiency is an oral therapy with iron-supplements, another option is the intravenous iron supplementation.

The oral supplementation causes side-effects such as nausea, vomiting, abdominal pain and many more in a lot of patients. There is a positive correlation between the appearance of gastrointestinal side-effects and the applicated iron dose.

Only a low fraction of orally taken iron is actually absorbed, even in patients with iron-deficiency. Since only a fraction of the orally administered iron is actually absorbed, the toxicity of high concentrations of iron in the gastrointestinal tract and the altered selection advantages of the bacteria presumably leads to microbiome changes.

The unabsorbed iron is potentially changing the microbiome, which leads to undesirable side effects.

With low-dose iron-supplementation the amount of unabsorbed iron is smaller, therefore a dosage dependent microbiome change would be expected.

The aim of the study is to determine the magnitude of the microbiome response to daily iron substitution with 12mg and 100mg.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Single Center Clinical Trial to Evaluate the Effect of Low-dose Versus Standard-dose Iron Supplementation on the Gut Microbiome in Non-anemic Iron-deficient Females
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard-dose

The standard-dose arm takes one 100mg of iron per day together with a meal, no matter breakfast, lunch or dinner - one tablet a day.

Dietary Supplement: Iron
4 weeks of daily oral iron therapy. The subjects administer the therapy themselves.

Experimental: Low-dose

The low-dose arm 12mg of iron a day. The first 6mg tablet in the morning on an empty stomach and the second 6mg tablet in the evening either one hour before or after eating - two tablets a day.

Dietary Supplement: Iron
4 weeks of daily oral iron therapy. The subjects administer the therapy themselves.

Outcome Measures

Primary Outcome Measures

  1. Microbiome diversity and oral iron therapy [4 weeks]

    The microbiome is analyzed using stool samples. A stool sample is taken before and after the 4 weeks period. The low-dose arm is expected to have a smaller decrease compared to the standard-dose arm. The microbiome composition is measured using 16S rDNA gene amplicon sequencing. The results are analysed using the Shannon-Index to include diversity as well as abundance.

Secondary Outcome Measures

  1. Side-effects of treatment [4 weeks]

    Adverse events will be assessed on a report form after 4 weeks

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Informed Consent as documented by signature

  • Female gender

  • Premenopausal

  • Age > 18 years

  • Regular menstrual cycle

  • BMI in normal range (18-25kg/m2)

  • Serum-ferritin ≤30ng/ml

  • No anemia (hemoglobin ≥117g/l)

  • No intake of dietary supplements for at least 4 weeks

Exclusion Criteria:
  • Pregnancy

  • Hypermenorrhea (more than 5 unties/tampons per day)

  • Chronic inflammatory disease, psychiatric disorders

  • Hypersensitivity to iron supplements

  • chronic kidney disease (creatinine >80 µmol/l)

  • Liver disease (ALT >35 U/l)

  • Hypo- or Hyperthyroidism (TSH not between 0.16-4.25 mU/l)

  • Intake of medicines that interact with oral iron supplementation (e.g. PPI)*

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Zurich

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Pierre-Alexandre Krayenbuehl, Professor Pierre-Alexandra Krayenbuehl, University of Zurich
ClinicalTrials.gov Identifier:
NCT05467423
Other Study ID Numbers:
  • IronGutMicrobiome
First Posted:
Jul 20, 2022
Last Update Posted:
Jul 27, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Pierre-Alexandre Krayenbuehl, Professor Pierre-Alexandra Krayenbuehl, University of Zurich
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 27, 2022